Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOTIVATE trial in hemophilia A patients with FVIII inhibitors
2024-516741-39-00Phase 4Authorised
- Sponsor
- Hämophilie-Zentrum Rhein Main
- Start
- Aug 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 4, open-label trial of simoctocog alfa, Octanate, von Willebrand factor concentrate, emicizumab, coagulation factor VIIa and 1 more in hemophilia A (3 arms), sponsored by Hämophilie-Zentrum Rhein Main. Planned start Aug 2024; status: authorised.
02
Drugs
simoctocog alfaOctanatevon Willebrand factor concentrateemicizumabcoagulation factor VIIa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2024-516741-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516741-39-00.